1
|
Aurer I, Neven A, Fiaccadori V, Counsell N, Phillips E, Clifton‐Hadley L, Fortpied C, Andre M, Federico M, Barrington S, Illidge T, Radford J, Raemaekers J. RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.71_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Aurer
- University Hospital Centre Zagreb Division of Hematology Department of Internal Medicine Zagreb Croatia
| | - A. Neven
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - V. Fiaccadori
- University College London Cancer Institute London UK
| | - N. Counsell
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - E. Phillips
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - L. Clifton‐Hadley
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - M. Andre
- Université Catholique de Louvain Department of Hematology Yvoir Belgium
| | - M. Federico
- University of Modena and Reggio Emilia CHIMOMO Department Modena Italy
| | - S. Barrington
- King's College London King's College London and Guy's and St Thomas' PET Centre London UK
| | - T. Illidge
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Radford
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Raemaekers
- Radboud University Medical Centre Department of Hematology Nijmegen Netherlands
| |
Collapse
|
2
|
Phillips EH, Counsell N, Illidge T, Andre M, Aurer I, Fiaccadori V, Fortpied C, Neven A, Federico M, Clifton‐Hadley L, Barrington S, Raemaekers J, Radford J. BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.115_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. H. Phillips
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - N. Counsell
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - T. Illidge
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - M. Andre
- CHU UCL Namur, Department of Haematology Yvoir Belgium
| | - I. Aurer
- University Hospital Centre Zagreb, Division of Hematology, Department of Internal Medicine Zagreb Croatia
| | - V. Fiaccadori
- University College London, Cancer Institute London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - A. Neven
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - M. Federico
- University of Modena and Reggio Emilia, CHIMOMO Department Modena Italy
| | - L. Clifton‐Hadley
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - S. Barrington
- King's College London and King's Health Partners, King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences London UK
| | - J. Raemaekers
- Radboud University Medical Center, Department of Haematology Nijmegen Netherlands
| | - J. Radford
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| |
Collapse
|
3
|
Conconi A, Vannata B, Janikova A, Ramirez A, Bodoni CL, Nowakowski G, Mian M, Ferreri AJ, Ryan G, Pangalis GA, Cabrera ME, Luminari S, Montoto S, Tsang R, Aurer I, Visco C, Mazzucchelli L, Trneny M, Gaidano G, Federico M, Lopez‐Guillermo A, Pro B, Zucca E. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31). Hematol Oncol 2021. [DOI: 10.1002/hon.78_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Conconi
- Azienda sanitaria locale Biella Ospedale degli Infermi ‐ Ematologia Biella Italy
| | - B. Vannata
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - A. Janikova
- University Hospital Brno Department of Hematology and Oncology Brno Czech Republic
| | - A. Ramirez
- Instituto Nacional de Cancerologia Hematology Department Mexico City Mexico
| | - C. Lobetti Bodoni
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - G. Nowakowski
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - M. Mian
- Ospedale di Bolzano Ematologia e Centro Trapianto Midollo Osseo Bolzano Italy
| | - Andrés J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Unità Operativa di Oncologia Medica Milano Italy
| | - G. Ryan
- Peter MacCallum Cancer Institute Deptment of Radiation Oncology Melbourne Australia
| | - G. A. Pangalis
- Athens Medical Center‐Psychikon Branch Hematology Department Athens Greece
| | - M. E. Cabrera
- Hospital del Salvador Facultad de Medicina Santiago Chile
| | - S. Luminari
- Arcispedale Santa Maria Nuova Servizio di Ematologia Reggio Emilia Italy
| | - S. Montoto
- St. Bartholomew’s Hospital Department of Medical Oncology London UK
| | - R. Tsang
- University Health Network Princess Margaret Hospital Toronto Canada
| | - I. Aurer
- University Hospital Centre Zagreb Division of Hematology Zagreb Croatia
| | - C. Visco
- University of Verona Departmento of Medicine ‐ Section of Hematology Verona Italy
| | | | - M. Trneny
- Charles University General Hospital Prague First Faculty of Medicine Prague Czech Republic
| | - G. Gaidano
- Azienda Ospedaliera "Maggiore della Carità" Ematologia Novara Italy
| | - M. Federico
- Università degli Studi di Modena e Reggio Emilia Centro Oncologico Modenese Modena Italy
| | | | - B. Pro
- Northwestern Medicine Hematology and Medical Oncology Chicago Illinois USA
| | - E. Zucca
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| |
Collapse
|
4
|
Bilic LG, Santek F, Soce M, Grah J, Kinda SB, Radman I, Mitrović Z, Martinović M, Aurer I. PO-0910: Efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00927-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Beijert M, Soubeyran P, El Badawy S, Specht L, Verschueren K, Ong C, Maazen R, Aurer I, Ta B, Neven A, Meulemans B, Fortpied C, Aleman B. OC-0374: Does low-dose TBI improve outcome in patients with early stage low grade NHL? (EORTC 20971-22997). Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00398-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Gac A, Chartier L, Girinsky T, Gotti M, Lazarovici J, Aurer I, Musto P, Damaj G, Federico M, Fortpied C, Raemaekers J, Meignan M, Hutchings M, Versati A, Andre M, Reman O. OUTCOME AND TREATMENT OF RELAPSING EARLY PET NEGATIVE PATIENTS INCLUDED IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Gac
- Institut d'Hématologie de Basse-Normandie; Centre Hospitalier Universitaire; Caen France
| | - L. Chartier
- Pôle Biométrie-Biostatistiques; LYSARC; Pierre Bénite France
| | - T. Girinsky
- Département de Radiothérapie; Institut de Cancérologie Gustave Roussy; Villejuif France
| | - M. Gotti
- Department of Hematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - J. Lazarovici
- Département d'Hématologie; Institut de Cancérologie Gustave Roussy; Villejuif France
| | - I. Aurer
- Zavod za Hematologiju; Klinike i Zavodi za Unutarnje Bolesti; Zagreb Croatia
| | - P. Musto
- Referral Cancer Center of Basilicata; IRCCS-CROB; Rionero in Vulture (Pz) Italy
| | - G. Damaj
- Département d'hématologie; université de Basse-Normandie; Caen France
| | - M. Federico
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - C. Fortpied
- Department of Statistic; EORTC; Brussels Belgium
| | - J. Raemaekers
- Department of Hematology; Radboud University Medical Center; Nijmegen Netherlands
| | - M. Meignan
- Département de Médecine Nucléaire; Hospital Henri Mondor; Creteil France
| | - M. Hutchings
- Department of Hematology; University Hospital Rigshospitalet; Copenhagen Denmark
| | - A. Versati
- Department of Nuclear Medicine; Arcispedale S. Maria Nuova; Reggio Emilia Italy
| | - M. Andre
- Département d'Hématologie; Université Catholique de Louvain; YVOIR Belgium
| | - O. Reman
- Institut d'Hématologie de Basse-Normandie; Centre Hospitalier Universitaire; Caen France
| |
Collapse
|
7
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
8
|
Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva M, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - C. Sarkozy
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - A. Lopez Guillermo
- Department of Hematology; Hospital Clinic, IDIBAPS, CIBERONC; Barcelona Spain
| | - M. Wondergem
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - E. Kimby
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Rusconi
- Division of Hematology; Niguarda Hospital; Milan Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Ospedale San Giovanni; Bellinzona Switzerland
| | - S. Montoto
- Department of Hematology; Barts Cancer Institute, QMUL; London UK
| | - M.G. da Silva
- Department of Hematology; Instituto Português de Oncologia de Lisboa; Lisbon Portugal
| | - I. Aurer
- Division of Hematology; University Hospital Centre Zagreb; Zagreb Croatia
| | - E. Paszkiewicz-Kozik
- Department of Lymphoid Malignancies; The Maria Sklodowska-Curie Memorial Institute and Oncology Centre; Warszawa Poland
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - F. Morschhauser
- Department of Clinical Hematology, CHU Lille, Unite GRITA; Universite de Lille 2; Lille France
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Chamuleau
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - S. Lockmer
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Minoia
- Haematology Unit, National Cancer Research Centre; Istituto Tumori "Giovanni Paolo II"; Bari Italy
| | - D. Issa
- Department of Hematology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch; Netherlands
| | - S. Alonso
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Conte
- Interdisciplinary Laboratory of Applied Research in Medicine (DReAM); University of Salento; Lecce Italy
| | - G. Salles
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - B. Coiffier
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| |
Collapse
|
9
|
Morello L, Rattotti S, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, El-Galaly T, Di Rocco A, Carli G, Defrancesco I, Giordano L, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Morello
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - S. Rattotti
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - T. van Meerten
- Department of Hematology; University Medical Center Groningen; Groningen The Netherlands
| | - K. Krawczyk
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - F. Moita
- Instituto Português de Oncologia de Lisboa, Francisco Gentil; Lisbon Portugal
| | - D. Marino
- Oncology Unit 1; Veneto Institute of Oncology IOV-IRCCS; Padova Italy
| | - S. Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences; University of Torino; Torino Italy
| | - M. Szymczyk
- Department of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology; Warsaw Poland
| | - I. Aurer
- Division of Hematology, Department of Internal Medicine; University Hospital Centre Zagreb; Zagreb Croatia
| | - T.C. El-Galaly
- Department of Hematology; Aalborg University Hospital; Aalborg Denmark
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G. Carli
- Department of Cell Therapy and Haematology; San Bortolo Hospital; Vicenza Italy
| | - I. Defrancesco
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| | - L. Giordano
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital Munich; Munchen Germany
| | - A. Santoro
- Department of Oncology and Hematology; Humanitas Clinical and Research Center, Rozzano, Italy; Rozzano (MI) Italy
| | - L. Arcaini
- Department of Hematology and Oncology, Fondazione IRCCS Policlinico S. Matteo; University of Pavia, Italy; Pavia Italy
| |
Collapse
|
10
|
Spina M, Nagy Z, Ribera J, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa A, Bosi A, Grosicki S, Glushko N, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego E, Baldini S, Scartoni S, Capriati A, Maggi C, Simonelli C. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv317] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Federico M, Spina M, Nagy Z, Ribera J, Aurer I, Jordan K, Borsaru G, Pristupa A, Bosi A, Grosicki S, Glushko N, Ristic D, Mayer J, Rossi C, Scordari A, Baldini S, Scartoni S, Maggi C, Capriati A, Simonelli C. Febuxostat a new weapon in armamentarium of tumor lysis syndrome management: results of Florence pivotal study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. J Chemother 2008; 20:640-4. [PMID: 19048695 DOI: 10.1179/joc.2008.20.5.640] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
We report the outcomes of 45 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) treated with a combination of ifosfamide, carboplatinum and etoposide (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods. The response rate (RR) to ICE was 47%, 2-year overall survival (OS) 31% and 2-year event-free survival (EFS) 22%. These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13%; p=0.355 for RR, 0.275 for OS, 0.668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. T) had no influence on prognosis. Changing from IMVP to ICE does not substantially improve the outcome of patients with relapsed or refractory aggressive NHL. Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone.
Collapse
Affiliation(s)
- I Aurer
- Department of Internal Medicine, University Hospital Center Rebro and Medical School, Zagreb, Croatia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Zupančić-Šalek S, Ajduković R, Bilić E, Peraica A, Femenić R, Rajić L, Aurer I, Pulanić D, Konja J, Labar B. OP05 ATG for pure red cell aplasia: case series. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70285-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Boban A, Zadro R, Bogdanić B, Mrsić S, Aurer I, Labar B. P032 Long term follow up of a patient with chronic myeloid leukemia treated with umbilical cord blood transplantation, buffy coat and interferon-α. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70380-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Aurer I. E13 Non-Hodgkin lymphoma: how to proceed. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70278-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Nemet D, Sertić D, Mrsić M, Bojanić I, Batinić D, Duraković N, Golubić-Ćepulić B, Serventi-Seiwerth R, Radman I, Aurer I, Zupančić-Šalek S, Labar B. E10 Stem cell transplantation for multiple myeloma in Croatia: evaluation of the efficacy of double autologous stem cell transplantation. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70275-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Radman I, Basić N, Labar B, Kovacević J, Aurer I, Bogdanić V, Zupancić-Salek S, Nemet D, Jakić-Razumović J, Mrsić M, Santek F, Grgić-Markulin L, Boban D. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002; 13:1650-5. [PMID: 12377656 DOI: 10.1093/annonc/mdf271] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The aim of this study was to analyze outcome of patients with Hodgkin's disease (HD) in whom first-line chemotherapy with mustine/vincristine/procarbazine/prednisone (MOPP) had failed. PATIENTS AND METHODS From January 1982 to December 1989 among 210 patients treated with MOPP and radiotherapy to initial bulky sites, 65 patients were primary refractory to or relapsed after initial treatment. RESULTS Twenty-nine of 65 patients (44%) were primary refractory to initial chemotherapy, 20 relapsed within 12 months after complete remission (CR) and 16 relapsed after CR that lasted more than 12 months. Patients with primary refractory HD and early relapse (<12 months after CR) were treated with doxorubicin/bleomycin/vinblastine/darcarbazine. In patients with late relapse (>12 months after CR) MOPP was repeated. The median follow-up for all patients was 115 months. The overall response rate was 63%. Thirty-three patients (51%) achieved a second CR and eight patients (12%) partial response. Remission rate was greatest in patients with late relapse (CR >12 months) (75 versus 55% for early relapse versus 35% for primary refractory HD) (P <0.01). At 10 years, overall and failure-free survival rates were 21 and 16%, respectively. Patients who were in first remission longer than 12 months had a superior overall survival (37 versus 18% for early relapse) and failure-free survival (24 versus 10% for early relapse). No patient with primary refractory HD was alive beyond 52 months after initial treatment failure (P <0.01). Main prognostic factors were duration of the first remission and tumor bulk at relapse. CONCLUSIONS Our results confirm previous observations that a significant proportion of patients with HD who experience induction treatment failure cannot be cured with conventional treatment and probably need more aggressive therapy.
Collapse
Affiliation(s)
- I Radman
- Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rebro, Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Huić D, Ivancević V, Aurer I, Dodig D, Nemet D, Labar B, Poropat M, Munz DL. Bone marrow immunoscintigraphy in haematological patients with pancytopenia: preliminary results. Nucl Med Commun 2002; 23:757-63. [PMID: 12124481 DOI: 10.1097/00006231-200208000-00009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The aim of this study was to assess the clinical value of bone marrow immunoscintigraphy using the (99m)Tc labelled anti-NCA-95 antigranulocyte antibodies (AGAb) and of AGAb bone marrow uptake ratio (UR) in the initial diagnostic work-up of diseases with depression of the bone marrow. Twenty-four whole-body bone marrow scans were performed in 23 patients (11 women, 12 men; median age 46 years, range 17-74 years) 5 h after i.v. injection of 370 MBq of AGAb. The UR was calculated from the posterior view drawing an irregular region of interest around the sacroiliac and a background areas. The mean UR in pancytopenic patients was 2.3+/-1.5 (range 0.3-5.8), thus being significantly lower (P=0.45 x 10(-6)) than the mean UR in a control group of 50 patients (mean UR 7.3+/-2.3; range 4.4-12.6) obtained previously. Considering patient age, there was no overlap between UR of pancytopenic patients and the respective normal ranges. The bone marrow appearance on scans seemed to be characteristic for the different haematological diseases investigated. In six patients with myelofibrosis, bone marrow scans demonstrated diffusely decreased bone marrow activity and prominent splenic uptake, possibly related to extramedullary haematopoiesis. In aplastic anaemia, highly reduced and patchy marrow uptake was observed in four patients (five scans), in one of them persisting even after blood cell counts had recovered to the near-normal range. In another two patients with aplastic anaemia, diffusely decreased bone marrow uptake was obtained. In patients with myeloid leukaemia, bone marrow patterns were almost normal probably because the target antigen is often expressed on neoplastic myeloid cells, too. Bone marrow extension was a common finding in these patients. There is an obvious differentiation between haematological patients with pancytopenia and normal subjects by means of AGAb bone marrow uptake ratio. The distinct patterns of AGAb distribution may be indicative for particular haematological diseases.
Collapse
Affiliation(s)
- Drazen Huić
- Clinical Department of Nuclear Medicine and Radiation Protection, University Hospital Rebro, Kispatićeva 12, 10000 Zagreb, Croatia.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Stanović Janda S, Boranić M, Sucić M, Petrovecki M, Golubić-Cepulić B, Aurer I, Labar B. Effects of a membrane-metallopeptidase blocking agent thiorphan in long-term cultures of human bone marrow. Haematologia (Budap) 2001; 30:289-302. [PMID: 11204028 DOI: 10.1163/156855900300109530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Thiorphan [(DL-3-mercapto-2-benzylpropanoyl)-glycine], a drug blocking the activity of membrane metalloendopeptidase EC 3.4.24.11 (CD10, CALLA), was added to long-term cultures of human bone marrow. Progression of the cultures was assessed by cell counts, cytology and clonogenic (GM-CFU) ability of the non-adherent cells in the supernatant and by morphology of the adherent stromal layer. A stimulatory effect on hematopoiesis was noted.
Collapse
Affiliation(s)
- S Stanović Janda
- Ruder Bosković Institute, Department of Molecular Medicine, Zagreb, Croatia.
| | | | | | | | | | | | | |
Collapse
|
20
|
Aurer I, Lauc G, Rendic D, Labar B. Aberrant immunoglobulin (IG) heavy chain glycosilation in igg multiple myeloma (MM). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81774-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Zadro R, Sucić M, Aurer I, Metelko-Kovacević J, Labar B, Rukavina AS. Analysis of clonality in T-lymphoproliferative diseases by multiplex PCR. Clin Chem Lab Med 1998; 36:637-9. [PMID: 9806476 DOI: 10.1515/cclm.1998.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Distinction between benign and malignant T-cell lymphoproliferative diseases can be difficult using morphological criteria. Using multiplex polymerase chain reaction system we have tested a series of patients with various lymphoproliferative disorders to detect clonal T-lymphocyte populations. Results show that clonal amplification products were obtained from all 10 patients with T-cell lymphoproliferative disorders while the amplification of DNA samples from B-cell neoplasms and normal individuals revealed polyclonal amplification products. By splitting the multiplex primer mix, the patient specific T-cell receptor gamma rearrangement was determined: five out of ten patients showed the exclusive presence of a single T-cell receptor gamma gene rearrangement. Three patients exhibited two rearranged T-cell receptor gamma genes, while in two patients positive reactions were obtained with three pairs of primers for variable and joining segments. Molecular analysis of rearranged T-cell receptor genes by multiplex polymerase chain reaction represents a useful and rapid tool for confirming diagnosis, to determine the extent of disease and to monitor the response to therapy.
Collapse
Affiliation(s)
- R Zadro
- Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and Clinical Hospital Center, Croatia
| | | | | | | | | | | |
Collapse
|
22
|
Bogdanić V, Aurer I, Labar B, Hitrec V, Nemet D, Mrsić M. Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation. Haematologica 1998; 83:575-6. [PMID: 9676036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Umbilical cord blood (UCB) is increasingly used as a source of hematopoietic progenitor cells for allotransplantation. Donor-derived buffy coat cells are considered optimal treatment for leukemia relapses after transplantation of allogeneic bone marrow. Experience with relapses after UCB transplants are sparse. Here we report a girl who received an UCB transplant for chronic myeloid leukemia, relapsed after three years, failed to respond to donor buffy coat cells, but achieved a complete hematologic, cytogenetic, and molecular remission on interferon-alpha.
Collapse
|
23
|
Bogdanić V, Aurer I, Hitrec V, Boban D, Nemet D, Zupancić-Salek S, Labar B. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation. Haematologica 1995; 80:338-40. [PMID: 7590504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
A patient relapsing with blastic lymphoid transformation of chronic myeloid leukemia after bone marrow transplantation received donor buffy-coat infusion. Low-dose chemotherapy was added because of a rapid WBC increase. Complete hematologic and cytogenetic remission was obtained. The patient remained in complete hematologic and cytogenetic remission for four months until he died in an accident. Two patients with acute leukemia failed to respond to a similar treatment.
Collapse
MESH Headings
- Acute Disease
- Adult
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Blast Crisis/drug therapy
- Blast Crisis/therapy
- Bone Marrow Transplantation
- Combined Modality Therapy
- Cytarabine/administration & dosage
- Daunorubicin/administration & dosage
- Fatal Outcome
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Leukemia, Myeloid/therapy
- Leukocyte Transfusion
- Male
- Methylprednisolone/administration & dosage
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Remission Induction
- Salvage Therapy
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- V Bogdanić
- Department of Internal Medicine, Medical School, Zagreb, Croatia
| | | | | | | | | | | | | |
Collapse
|
24
|
Nemet D, Grahovac B, Labar B, Mrsić M, Radman I, Bogdanić V, Hitrec V, Zaher D, Aurer I, Sertić D. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy. Haematologica 1995; 80:238-40. [PMID: 7672716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Five acute promyelocytic leukemia (APL) patients who achieved a complete remission (CR) with all-trans retinoic acid (ATRA) underwent residual disease monitoring through reverse transcription polymerase chain reaction (PCR) for PML/retinoic acid receptor-alpha (PML/RAR alpha) fusion transcript. All received consolidation chemotherapy in CR, one in the form of autologous bone marrow transplantation (ABMT). In four of the patients PCR was positive for the PML/RAR alpha transcript immediately after ATRA treatment and/or after the first consolidation chemotherapy course. In the patient treated with ABMT, positivity was still detected six months after ABMT. One patient given five repeated courses of chemotherapy was PCR negative for PML/RAR alpha after 14 months in CR. Our pilot study confirmed that ATRA is a highly efficient induction therapy for APL in various stages of the disease, but ATRA alone cannot cure the disease. PCR should be considered a fundamental assay for assessing minimal residual disease in CR that will influence further treatment strategies and permit evaluation of treatment results.
Collapse
Affiliation(s)
- D Nemet
- Department of Medicine, University Hospital Rebro, Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Maravić N, Bogdanić V, Aurer I, Nemet D, Labar B. Severe hyperlipidemia following treatment with PUVA for acute skin GVHD. Bone Marrow Transplant 1994; 14:173. [PMID: 7951110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
26
|
Abstract
RAS mutations are found in about 25% of acute myeloid leukemia (AML) cases. The importance of these changes is unknown. If RAS mutations confer growth advantage to leukemia subclones in which they emerge, substantially more nonconservative than conservative mutations should be found. The incidence of conservative mutations was not reported previously. We sequenced N-RAS and K-RAS codons 12 and 13 and N-RAS codon 61 in 20 subjects with newly diagnosed AML. Four nonconservative N-RAS mutations and 4 conservative K-RAS mutations were found. There were no differences between subjects with AML and nonconservative RAS mutations and those with conservative or without RAS mutations. Additional studies are needed to examine the incidence of conservative RAS mutations in subjects with AML.
Collapse
Affiliation(s)
- I Aurer
- Department of Internal Medicine, Medical School and University Hospital Rebro, Zagreb, Croatia
| | | | | | | | | | | |
Collapse
|
27
|
Bogdanić V, Nemet D, Kastelan A, Latin V, Petrovecki M, Brkljacić-Surlaković L, Kerhin-Brkljacić V, Aurer I, Konja J, Mrsić M. Umbilical cord blood transplantation in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Transplantation 1993; 56:477-9. [PMID: 8356607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- V Bogdanić
- Department of Internal Medicine, University Hospital Center and Medical School, University of Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Aurer I. [Critical review of drugs in 1991]. Lijec Vjesn 1993; 115:189-90. [PMID: 7508073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
29
|
Abstract
We report a case of pre-B-cell acute lymphoblastic leukemia (ALL) with the Ph1-chromosome, t(9;22) translocation and P190 associated BCR/ABL rearrangement. One cell with the Ph1-chromosome and t(9;22) also had del(5q). Interestingly, another diploid cell with iso(17q) lacked the Ph1-chromosome and t(9;22). This finding, similar to one reported in chronic myelogenous leukemia, is consistent with the possibility that abnormality manifest as chromosome instability antedates the Ph1-chromosome and t(9;22) in some cases of Ph1-chromosome positive acute leukemia.
Collapse
Affiliation(s)
- I Aurer
- Department of Medicine, UCLA School of Medecine 90024-1678
| | | | | | | |
Collapse
|
30
|
Labar B, Mrsić M, Pavletić Z, Bogdanić V, Nemet D, Aurer I, Radman I, Filipović-Grcić N, Sertić D, Kalenić S. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11:379-82. [PMID: 8504271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Between October 1988 and December 1990, 60 patients with leukaemia (25 with AML, 19 ALL and 16 CML) undergoing BMT were randomised in a double-blind clinical trial to receive prostaglandin E2 (PGE) (Prostin E2, 0.5 mg per tablet) or placebo for prophylaxis of oral mucositis. Patients had to dissolve tablets in the mouth three times daily starting 7 days before BMT and continuing until 21 days after BMT. The incidence of severe oral mucositis was similar for both groups, 55% in patients receiving PGE and 52% in patients receiving placebo. The duration of severe mucositis did not differ between PGE and placebo groups (chi-square 0.95, p = NS). The incidence of HSV infection was significantly higher in patients receiving PGE. Patients with HSV infection receiving PGE also had a higher incidence of severe oral mucositis. The results presented indicate that PGE is not effective for prophylaxis of oral mucositis in BMT recipients.
Collapse
Affiliation(s)
- B Labar
- Department of Medicine, School of Medicine, University of Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Mrsić M, Nemet D, Labar B, Bogdanić V, Radman I, Zupancić-Salek S, Kovacević-Metelko J, Aurer I, Maravić N. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. Transplant Proc 1993; 25:1268-70. [PMID: 8442109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- M Mrsić
- Department of Medicine, University Hospital Rebro, Zagreb, Croatia
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Aurer I, Juhbashi T, Sekine I, Tomonaga M, Gale RP. Analysis of BCR/ABL abnormalities in mRNA from 20-year-old paraffin-embedded tissue for BCR/ABL rearrangement by polymerase chain reaction. Acta Haematol 1993; 90:5-7. [PMID: 8237276 DOI: 10.1159/000204364] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We studied whether it is possible to obtain sufficient mRNA from old paraffin-embedded samples of spleen and bone marrow for reverse transcription and polymerase chain reaction analysis. Spleen tissue from 6 subjects with chronic myelogenous leukemia was studied for rearrangement of BCR and ABL genes. Analysis was successful in 4 cases. These data indicate the feasibility of retrospective analysis of tissue samples of special interest by molecular techniques.
Collapse
Affiliation(s)
- I Aurer
- Department of Medicine, UCLA School of Medicine 90024-1678
| | | | | | | | | |
Collapse
|
33
|
Labar B, Bogdanić V, Nemet D, Kovacević-Metelko J, Mrsić M, Pavletić Z, Zupancić-Salek S, Radman I, Aurer I. Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. Bone Marrow Transplant 1992; 10:471-2. [PMID: 1464014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A patient developed pure red cell aplasia after ABO incompatible BMT for leukemia. He did not respond to plasma exchange. Antilymphocyte globulin therapy was followed by complete and permanent erythroid recovery with disappearance of recipient-derived isoagglutinins.
Collapse
Affiliation(s)
- B Labar
- Department of Internal Medicine, School of Medicine, University of Zagreb, Croatia
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Aurer I, Canaani E, Gale RP. Hypothesis: additional cytogenetic abnormalities and progression to acute phase in chronic myelogenous leukemia. Leukemia 1991; 5:1012-3. [PMID: 1961031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- I Aurer
- Department of Internal Medicine, University Hospital Rebro, Zagreb, Croatia, Yugoslavia
| | | | | |
Collapse
|
35
|
Aurer I, Butturini A, Gale RP. BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1991; 78:2407-10. [PMID: 1932752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II. Ph1-chromosome positive CML is uncommon in children and it is unknown whether these children have similar rearrangements. We studied 17 children with Ph1-chromosome positive CML. Five were studied for Mbcr rearrangement using Southern blotting, nine for the presence of chimeric BCR-ABL mRNA using reverse transcription and polymerase chain reaction, and three for both. All eight children studied by Southern blotting had BCR rearrangement. Of 12 children in whom BCR-ABL mRNA was studied, 10 had Mbcr exon 2 joined to ABL exon II, one had Mbcr exon 3 joined to ABL II, and one had both Mbcr-ABL junctions. These data indicate a similarity to adult CML. However, mRNA processing in children may preferentially splice Mbcr exon 2 to ABL exon II. No child had BCR exon 1 joined to ABL exon II, the rearrangement typical of childhood Ph1-chromosome positive acute lymphoblastic leukemia.
Collapse
Affiliation(s)
- I Aurer
- Department of Medicine, UCLA School of Medicine 90024-1678
| | | | | |
Collapse
|
36
|
Aurer I, Gale RP. Are new conditioning regimens for transplants in acute myelogenous leukemia better? Bone Marrow Transplant 1991; 7:255-61. [PMID: 2070130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Pretransplant conditioning regimens designed to decrease leukemia relapse and increase leukemia-free survival in allotransplants in acute myelogenous leukemia (AML) were developed recently. We review studies of new regimens containing drugs like busulfan, cytarabine, melphalan or etoposide as well as novel radiation schemes. Results are compared to those achieved with cyclophosphamide and total body radiation. Some new regimens seem inferior. Others seem to decrease relapse but do not improve leukemia-free survival because of increased deaths from causes other than leukemia. In a third group of new regimens reporting improved antileukemia efficacy and increased leukemia-free survival, results are not convincingly superior to cyclophosphamide and total body radiation. This failure to detect major improvements with new conditioning regimens may indicate the relative insensitivity of current clinical trial designs to detect improvement or the absence of an effective dose-response relationship in AML.
Collapse
Affiliation(s)
- I Aurer
- Department of Medicine, UCLA School of Medicine 90024-1678
| | | |
Collapse
|
37
|
Aurer I, Ribas A, Gale RP. Hematopoietic growth factors in bone marrow transplantation: current and future directions. Haematologica 1991; 76:85-8. [PMID: 1682224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
|
38
|
Aurer I, Ribas A, Gale RP. What is the role of recombinant colony stimulating factors in bone marrow transplantation? Bone Marrow Transplant 1990; 6:79-87. [PMID: 2207455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Colony stimulating factors (CSFs) regulate production of myeloid cells. Use of CSFs post bone marrow transplant accelerates granulocyte recovery by shortening the interval of relative but not absolute granulocytopenia. Data from non-randomized trials suggest that CSFs decrease documented infections by about one-third; there is no apparent increase in survival. Adverse effects of CSFs are modest; there are no indications of increased graft failure, graft-versus-host disease or cancer recurrence after their use. Future studies of CSFs should be in the context of randomized trials where their therapeutic efficacy is best evaluated. CSFs may also be useful in other transplant settings such as treating graft failure or increasing the efficiency of harvesting myeloid progenitor cells from the blood for subsequent transplantation. Controlled trials are needed to evaluate these uses. Future directions will probably include combinations of CSFs and, possibly, in vitro treatment of the graft.
Collapse
Affiliation(s)
- I Aurer
- Department of Medicine, UCLA School of Medicine 90024-1678
| | | | | |
Collapse
|
39
|
Zupancić-Salek S, Aurer I, Bogdanić V, Nemet D, Mrsić M, Labar B. Donor characteristics in allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4 Suppl 3:107. [PMID: 2627595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- S Zupancić-Salek
- Department of Medicine, University Hospital Rebro, Zagreb, Yugoslavia
| | | | | | | | | | | |
Collapse
|
40
|
Labar B, Bogdanić V, Nemet D, Mrsić M, Pavletić Z, Zupancić S, Radman I, Aurer I. Allogeneic BMT for AML in Zagreb. Bone Marrow Transplant 1989; 4 Suppl 3:86-7. [PMID: 2697413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- B Labar
- Department of Medicine, Clinical Hospital Center-Rebro, Zagreb, Yugoslavia
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Bogdanić V, Labar B, Nemet D, Mrsić M, Pavetić Z, Aurer I. Allogeneic bone marrow transplantation for ALL in Zagreb. Bone Marrow Transplant 1989; 4 Suppl 3:88-9. [PMID: 2697414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- V Bogdanić
- Department of Medicine, University Hospital Rebro, School of Medicine, Zagreb, Yugoslavia
| | | | | | | | | | | |
Collapse
|
42
|
Aurer I, Labar B. [Oncogenes in acute myeloid leukemia]. Lijec Vjesn 1989; 111:474-8. [PMID: 2699910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The role of oncogenes in carcinogenesis is intensively studied. Certain oncogenes are often found in some kinds of tumors. In acute myeloid leukemia (AML), of all oncogenes presently known, only those belonging to the ras group are activated in a larger number of cases. In single cases myc, myb, sis, and ets oncogenes have been found. It is possible that a disorder in regulation of myc and myb protooncogenes exists in AML.
Collapse
|
43
|
Aurer I, Kolevska T, Labar B, Kracun I, Nemet D, Marusić M, Bogdanić V. [Bone marrow cultures from patients with acute myeloid leukemia]. Lijec Vjesn 1988; 110:405-9. [PMID: 3246937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|